MDxHealthMDXH
MDXH
About: MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
Employees: 300
0
Funds holding %
of 6,810 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
144% more funds holding
Funds holding: 9 [Q2] → 22 (+13) [Q3]
126% more capital invested
Capital invested by funds: $21M [Q2] → $47.4M (+$26.4M) [Q3]
50.85% more ownership
Funds ownership: 32.78% [Q2] → 83.63% (+50.85%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
203%
upside
Avg. target
$6.50
228%
upside
High target
$7
254%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Jason Bednar 43% 1-year accuracy 16 / 37 met price target | 203%upside $6 | Overweight Maintained | 7 Nov 2024 |
Lake Street | 254%upside $7 | Buy Initiated | 31 Oct 2024 |
Financial journalist opinion
Positive
Seeking Alpha
4 weeks ago
MDxHealth: Strong Buy On Its Cutting-Edge Urology Diagnostics
MDxHealth SA offers a comprehensive portfolio of precision diagnostics targeting all stages of prostate cancer and advanced UTI detection, addressing a $4.9 billion TAM. The company's flagship products, ConfirmMDx (post-biopsy detection), SelectMDx (pre-biopsy screening), and GPS (treatment planning), are driving clinical adoption. MDxHealth achieved 21% YoY revenue growth in Q3 2024, with management forecasting positive EBITDA by 2025 through disciplined cash management and market penetration.
Neutral
GlobeNewsWire
1 month ago
MDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City.
Neutral
Seeking Alpha
2 months ago
MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Michael K. McGarrity - Chief Executive Officer and Director Ron Kalfus - Chief Financial Officer Conference Call Participants Vidyun Bais - BTIG Thomas Flaten - Lake Street Capital Markets Jason Bednar - Piper Sandler Operator Good day, and welcome to the MDxHealth Third Quarter 2024 Earnings Call.
Neutral
GlobeNewsWire
2 months ago
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K.
Neutral
GlobeNewsWire
3 months ago
MDxHealth Announces Pricing of Offering of Ordinary Shares
MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“Ordinary Shares”) in a registered public offering (the “Offering”) at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducting commissions and estimated offering expenses. A strategic partner is purchasing 1,500,000 Ordinary Shares in this Offering directly from the Company rather than through the underwriters.
Neutral
GlobeNewsWire
3 months ago
MDxHealth Announces Launch of Offering of Ordinary Shares
MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40.0 million of ordinary shares of the Company without nominal value ("Ordinary Shares") in a registered public offering (the “Offering”). The Company also expects to grant the underwriters a 30-day option to purchase up to 15% of the Ordinary Shares being offered, excluding any Ordinary Shares purchased directly from the Company in the Offering pursuant to any separate Securities Purchase Agreement.
Neutral
Seeking Alpha
4 months ago
MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q2 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Vidyun Bais - BTIG Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Operator Greetings, and welcome to the MDxHealth Second Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this call is being recorded.
Neutral
InvestorPlace
4 months ago
MDXH Stock Earnings: MDxHealth Misses EPS, Beats Revenue for Q2 2024
MDxHealth (NASDAQ: MDXH ) just reported results for the second quarter of 2024. MDxHealth reported earnings per share of -42 cents.
Neutral
GlobeNewsWire
4 months ago
MDxHealth Reports Q2 and Half Year 2024 Results
MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 million Year-over-year H1 revenues increase by 34% to 42.0 million Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the second quarter and half year ended June 30, 2024. Michael K.
Neutral
GlobeNewsWire
5 months ago
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and six-month period ended June 30, 2024, after market close on Wednesday, August 21, 2024. Title: MDxHealth Presents Second Quarter and First Half 2024 Financial Results and Corporate Update Conference Call and Webcast Speakers: Michael K.
Charts implemented using Lightweight Charts™